

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeINFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)Atty. Docket No. 45775-Z/IPW/AJM/DNS  
Serial No. 10/813,322Applicants:  
Christina Kabbash et al.Filing Date  
March 29, 2004Group  
1618

U.S. PATENT DOCUMENTS									
Examiner's Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate			
RE	US 4 1 6 3 8 5 9	8/7/99	Sprenger et al.;						

  

FOREIGN PATENT DOCUMENTS									
Examiner's Initial	Document Number	Date	Country	Class	Subclass	Translation Yes	No		
RE	WO 9 3 0 3 7 1 6	PCT	WO						

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

- Armani, G. et al. (1972) Synthesis and Pharmacological Activity of Some Chloropenesin Phenoxyalkanoates, *Farmaco-Ed.Sc.* Vol. 27, pp. 870-875;
- Chak, W. et al. (1981) Effects of Metabolic Inhibitors on Extracellular Fructosyltransferase Production in *Actinomyces Viscosus*, *Infection and Immunity* Vol. 34(3), pp. 930-937;
- Gao, P. et al. (1991) Inhibition of Organic Anion Transport in J774 Macrophage-like Cells Potentiates the Ability of Norfloxacin to Inhibit the Intracellular Growth of *Listeria-monocytogenes* in these Cells, *Program and Abstracts of the Interscience Conference on Antimicrobial* Vol. 31, pp. 106;
- Kabara, J. J. (1976) The Effect of Clofibrate and other Hypocholesteremic Drugs on Microorganisms, *Artery* Vol. 2(6), pp.497-518;
- Kusaka, T. et al. (1976) Studies on Uptake of Fatty Acids into Mycobacterial Cells, *J. Kawasaki Medical Journal* Vol. 1(4), pp. 153-162;
- Powanda, M.C. et al. (1976) Protective Effect of Clofibrate Against *S. Pneumoniae* Infection in Rats, *Proceedings of the Society for Experimental Biology and Medicine* 152(3), pp. 437-440
- Rudin, D.E. et al. (1992) Gemfibrozil Enhances the Listericidal Effects of Fluoroquinolone Antibiotics in J774 Macrophages, *J. Exp. Med.* Vol. 176, pp. 1439-1447;
- Smith, P.F. et al. (1966) Growth Inhibition of Mycoplasma by Inhibitors of Polyterpene Biosynthesis and its Reversal by Cholesterol, *J. of Bacteriology* 91(5), pp. 1854-1858; and
- Yajko, D.M. et al. (1995) Gemfibrozil Enhances the Intracellular Activity of Ciprofloxacin Against *Mycobacterium Avium* Complex (MAC), Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy

EXAMINER

DATE CONSIDERED

2/21/05

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicants: Christina Kabbash et al.  
Serial No.: 10/813,322  
Filed: March 29, 2004  
Exhibit A

BEST AVAILABLE COPY

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 45775-Z/JW/AJM/DNS		Serial No. Not Yet Known	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicants: Christina Kabbash, et al.			
				Filing Date Herewith		Group 1618	
U.S. PATENT DOCUMENTS							
Examiner Initial	Document Number			Date	Name	Class	Filing Date if Appropriate
NO	09 4 3 8 1 4 4			11/10/99	Kabbash et al.;		
	4 8 5 9 7 0 3			8/22/89	Krauser;		
	6 5 3 1 2 9 1			3/11/03	Kabbash et al.;		
	4 8 9 1 2 2 0			1/2/90	Donzis et al.;		
	5 4 2 2 3 7 2			6/6/95	Silverstein et al.;		
	5 8 3 7 4 8 0			11/17/98	Sacchetti et al.;		
	3 6 7 4 8 3 6			7/4/72	Creger;		
FOREIGN PATENT DOCUMENTS							
	Document Number			Date	Country	Class	Subclass
	WO 99 37800			7/99	WO		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
NO	The Merck Index, 10 <sup>th</sup> Ed., Merck & Co., Inc., Rahway, New Jersey, 1983, No. 4246;						
	Vernon et al. (1984) The Presence of Essential Arginine Residues at the NADPH-Binding Sites of $\beta$ -Ketoacyl Reductase, And Enoyl Reductase Domains of the Multifunctional Fatty Acid Synthetase of Chicken Liver, <i>Biochim. et Biophys. Acta.</i> Vol. 788, pp. 124-131;						
	Cléments et al. (1982) Irreversible Inhibition of Fatty Acid Synthase From Rat Mammary Gland With S-(4-bromo-2,3-dioxobutyl)-CoA. <i>Biochem. J.</i> Vol. 207, pp. 291-296;						
	Bergler, H. et al. (1996) The enoyl-[acyl-carrier-protein] reductase (FabI) of <i>Escherichia coli</i> , which catalyzes a key regulatory step in fatty acid biosynthesis, accepts NADH and NADPH as cofactors and is inhibited by palmitoyl-CoA. <i>Eur. J. Biochem.</i> Vol. 242, pp. 689-694;						
	Heath, R.J. and Rock, C.O. (1996) Regulation of Fatty Acid Elongation and Initiation by Acyl-Acyl Carrier Protein in <i>Escherichia coli</i> . <i>J. Biol. Chem.</i> Vol. 271, No. 4, pp. 1833-1836;						
	Cardon, J. W. and Hammes, G.G. (1983) Kinetic and Structural Investigation of Acyl-binding Sites on Avian Fatty Acid Synthase. <i>J. Biol. Chem.</i> Vol. 258, No. 8, pp. 4802-4807;						
	International Publication No. WO 99/57800, published July 29, 1999, Levy, S.B. and McMurry, L.M. for Antimicrobial Compounds, PCT International Application No. PCT/US99/01288, filed January 22, 1999;						
	Amigo, L. et al. (1992) Subcellular distribution and characteristics of ciprofibril-CoA synthetase in rat liver. <i>Biochem. J.</i> Vol. 284, pp. 283-287;						
	Bronfman, M., et al. (1992) Hypolipidaemic drugs are activated to acyl-CoA esters in isolated rat hepatocytes. <i>Biochem. J.</i> Vol. 284, pp. 289-295;						
	Urrea, R. and Bronfman, M. (1996) Species Differences in the Intracellular Distribution of Ciprofibril-CoA hydrolase. Implications for peroxisome proliferation. <i>FEBS Letters.</i> Vol. 389, pp. 219-223;						
	Hashimoto, et al. (1997) Effect of gemfibrozil on centrifugal behavior of rat peroxisomes and activities of peroxisomal enzymes involved in lipid metabolism. <i>Bio Pharm. Bull.</i> Vol. 20, No. 4, pp. 315-321;						
	Baldock et al., (1996) A Mechanism of Drug Action Revealed by Structural Studies of Enoyl Reductase. <i>Science.</i> Vol. 274, pp. 2107-2110.						
EXAMINER <i>NO Jones</i>				DATE CONSIDERED <i>4/21/05</i>			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

10/813,322

BEST AVAILABLE COPY

